Symptomatic carotid stenosis: is stenting as safe and effective as carotid endarterectomy?

David Calvet1, Jean-Louis Mas,

  • 1Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France.

Insights

Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are equally effective for preventing recurrent stroke. CAS has higher procedural risks but is a safe alternative for select patients, especially those under 70.

Area of Science:

  • Vascular Surgery
  • Neurology
  • Interventional Cardiology

Background:

  • Symptomatic carotid stenosis poses a significant risk of ipsilateral stroke.
  • Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are primary interventions to prevent stroke in these patients.
  • Comparative evidence between CAS and CEA is crucial for clinical decision-making.

Purpose of the Study:

  • To review current evidence comparing carotid artery stenting (CAS) with carotid endarterectomy (CEA).
  • To evaluate the efficacy and safety of both procedures in preventing ipsilateral stroke in patients with symptomatic carotid stenosis.

Main Methods:

  • Systematic review of randomized clinical trials and registries.
  • Analysis of individual patient data from the Carotid Stenosis Trialists' Collaboration.

Main Results:

  • CAS is associated with a higher risk of procedural stroke or death compared to CEA.
  • CAS shows a lower risk of procedural myocardial infarction and local complications.
  • Both CAS and CEA demonstrate equal effectiveness in preventing late recurrent ipsilateral stroke.
  • Restenosis rates are similarly low for both procedures.
  • Individual patient data confirmed CAS safety and efficacy in patients younger than 70.

Conclusions:

  • Carotid endarterectomy (CEA) remains the standard treatment for symptomatic carotid stenosis.
  • Carotid artery stenting (CAS) is a safe and effective alternative, particularly for patients under 70.
  • CAS can be considered when CEA is contraindicated.
Abstract

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
422
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
472
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541